论文部分内容阅读
《药品非临床研究质量管理规范》(GLP)在药物临床前研究中发挥重要作用,同时也是药物研发过程中的重要环节.中国有关GLP的相关工作起步于上世纪90年代末期.经历近20年的飞速发展,我国已经完成了GLP体系的初步建设工作.本文首先回顾了该领域GLP机构的基本情况,介绍了中国GLP机构的年增长数及总数的变化情况、现有GLP机构类型及其具体服务能力,而后选择“十一五”、“十二五”期间受到新药重大专项支持的部分机构进行了重点介绍.虽然我国GLP机构在硬件和软件的建设中都取得了重大进展,但仍存有一些问题,如创新能力不足,故我国GLP的建设仍需进一步完善和发展.“,”Good laboratory practice (GLP) plays an important role in pre-clinical studies,which are a key stage in new drug research and development (R&D).The development of GLP in China started in the late 1990s.Following 20 years of developments,GLP system has already been established in this country.This review firstly evaluated all the institutions in this field,and described the annual number and total number of institutions,the distribution of GLP institutions,the types of GLP institutions,and the service provided by these GLP institutions.Since the initiation of the National Key Technology R&D Program during the 11th Five-Year Plan,it had a significant effect on the development of GLP.Therefore,the institutions which have undertaken projects from this program will be introduced later.We also described the infrastructure of hardware and software in GLP institutions along with their faults,such as variation in development and the lack of innovation.